Table 1 Bone marrow biopsy, blood test results, and clinical assessment from diagnosis, remission and relapse
Variable | Diagnosis | 21 days post induction chemotherapy | 23 days post salvage chemotherapy | 2 months into ascorbate treatment | Relapse | Relapse post induction chemotherapy | Relapse | Relapse | Normal range |
|---|---|---|---|---|---|---|---|---|---|
Timeline (months post diagnosis) | 0 | 1 | 2 | 4 | 34 | 36 | 38 | 41 | Â |
Bone marrow blast count (% of nucleated cells) | 75 | 30–80 | 57–65 | 0 | 76 | >90 | 61–85 | 96 | <5 |
Hemoglobin (g/dL) | 9.8 | 11.2 | 9.7 | 13.3 | 11.0 | 9.6 | 12.1 | 9.9 | 13.0–17.5 |
White Cell Count (×109/L) | 1.53 | 1.08 | 0.26 | 3.2 | 1.6 | 1.6 | 2.1 | 3.6 | 4.0–11.0 |
Neutrophils (×109/L) | 0.14 | 0.46 | 0.0 | 1.8 | 0.4 | 0.29 | 1.3 | 0.36 | 1.9–7.5 |
Circulating blasts (×109/L) | 0.2 | 0.0 | 0.0 | 0.0 | Occasional | 0.04 | 0.0 | 2.4 | 0 |
Platelets (×109/L) | 73 | 228 | 16 | 83 | 89 | 89 | 116 | 36 | 150–400 |
Molecular Pathologya | NPM1+ve | NDb | ND | NPM1–ve | ND | ND | ND | ND |  |
Clinical assessment | Acute Myeloid Leukemia | Refractory to chemotherapy | Refractory to chemotherapy | Clinical remission | Relapse | Refractory to chemotherapy | Persistent AML | Persistent AML | Â |
